Barinthus Biotherapeutics (BRNS) Cash from Investing Activities (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Cash from Investing Activities came in at $55000.0 in Q1 2026, up 1200.0% YoY from $4230.8 in Q1 2025, and up 2650.0% on a QoQ basis from $2000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Cash from Investing Activities data on file, last reported at $55000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 1200.0% year-over-year to $55000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $476000.0 (up 180.81% YoY) and the FY2025 annual result came in at $416000.0, up 146.64% from the prior year.
- Cash from Investing Activities rose to $55000.0 in Q1 2026, from $2000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $451000.0 in Q3 2025 to a low of -$3.0 million in Q2 2023.
- A 5-year average of -$681411.8 and a median of -$192000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 1476.56% — and 2026, when it soared 1200.0%.
- Tracing BRNS's Cash from Investing Activities over 5 years: stood at -$586000.0 in 2022, then jumped by 126.11% to $153000.0 in 2023, then sank by 281.7% to -$278000.0 in 2024, then soared by 100.72% to $2000.0 in 2025, then surged by 2650.0% to $55000.0 in 2026.
- The last three Cash from Investing Activities figures came in at $55000.0 (Q1 2026), $2000.0 (Q4 2025), and $451000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 61,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61,000.00 |
| Jun 30, 2026 | 61,000.00 |
| Mar 31, 2026 | 55,000.00 |
| Mar 31, 2026 | 55,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 451,000.00 |
| Sep 30, 2025 | 451,000.00 |
| Jun 30, 2025 | -32,000.00 |
| Jun 30, 2025 | -32,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | -278,000.00 |
| Dec 31, 2024 | -278,000.00 |
| Sep 30, 2024 | -114,000.00 |
| Sep 30, 2024 | -114,000.00 |
| Jun 30, 2024 | -192,000.00 |
| Jun 30, 2024 | -192,000.00 |
| Mar 31, 2024 | -308,000.00 |
| Mar 31, 2024 | -308,000.00 |